Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154316 | 0.91 | PTPN11 (0.81) | PTPN11KCNH2EGFR | |
| SCHEMBL25514319 | 0.91 | PTPN11 (0.84) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL23083714 | 0.90 | PTPN11 (0.76) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL25514482 | 0.90 | PTPN11 (0.76) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL23083932 | 0.89 | PTPN11 (0.75) | PTPN11KCNH2EGFR | |
| SCHEMBL23083707 | 0.89 | PTPN11 (0.75) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL23083765 | 0.89 | PTPN11 (0.75) | PTPN11KCNH2EGFR | |
| SCHEMBL23083704 | 0.89 | PTPN11 (0.75) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL24233652 | 0.89 | PTPN11 (0.81) | PTPN11KCNH2EGFRMAPK3MAPK1 | |
| SCHEMBL19785043 | 0.89 | PTPN11 (1.00) | PTPN11KCNH2EGFRMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2021043077-A1 | SUBSTITUTED PYRAZINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885KCNH2 2485/4885EGFR 2069/4885 |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | PTPN11 12/4885KCNH2 3436/4885EGFR 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.